With the ascendance of large genomic biobanks that leverage healthcare systems and provide access to DNA, biospecimens and electronic health record (EHR) data, epidemiologists can now conduct population science research at scale in individual cohorts with sample sizes far exceeding 100,000 participants. Largescale biobanks like UK Biobank, that are nested within a national or regional health system, are creating platforms for research that holds the promise to translate genomic medicine findings into "precision" approaches for both individual patient care and population prevention. The current wave of genomic biobanks represents the most recent in a series of eras of individual smaller prospective cohort studies that began in the mid 1900s and provided initial evidence that led to targeted prediction, prevention and treatment approaches ( Table 1) .
The iconic Framingham Heart Study (FHS) provides a useful illustration: the first FHS publication describing "factors of risk" for prediction of coronary heart disease was published well over a decade after initiation of the first FHS examination [1] . Prospective associations of individual risk factors were subsequently validated in independent cohorts and large meta-analyses, and the totality of randomized clinical trials have demonstrated clear benefits from therapies to reduce the level and burden of risk factors and have led to clear guidelines for prevention and/or treatment based on strata of risk, for example for elevated blood pressure [2] and elevated LDL-cholesterol [3] . Framingham multivariable risk strata [4] represent a precursor to "stratified" or "personalized' prediction, and multivariable risk factor algorithms calibrated to race/ethnicity are now incorporated into treatment guidelines [2, 3] . Importantly, the time interval from discovery to clinical/population implementation has typically been measured in decades not years. In the early days of prospective cohort studies, collaboration among cohorts was rare; however, with the advent of genome-wide association studies (GWAS) at the turn of the century, large international genomics consortia, such as CHARGE [5] , GIANT [6] , and PGC [7] , have thrived based upon collaboration among scores of individual cohorts.
The UK Biobank consists of more than 500,000 men and women who were enrolled during 2006-2010 (age range 40-69 years) and for whom health data is being collected over the long term. Since 2012, UK Biobank data has been available to researchers, without exclusive or preferential access, for health-related research inquiry [8] . This democratic and streamlined access to UK Biobank data by researchers across the world is supported by the informed consent of UK Biobank participants and has provided breathtaking opportunities for rapid conduct of big data research using genotype and phenotype at a scale not previously seen in biomedical research.
Given the rapidly increasing rate of research publications using UK Biobank data, it is not unreasonable to evaluate the quality and content of research emanating from initial studies derived from this influential biobank and to assess these research findings in the context of potential impact on population health. In the current issue of European Journal of Epidemiology, Glynn and Greenland [9] conducted a comprehensive review of the highest impact published findings from the UK Biobank defined by citations, alternative metric data, or publication in a high impact journal. Of the nearly 700 studies published in the first 7 years of the UK Biobank and first 4 years of access to genotyping data, many published manuscripts have provided novel associations or replication of known associations. However, there have been few studies demonstrating "a method of patient selection or prediction model that enabled significant improvement in prediction, improved risk assessment, more targeted screening, and/or more targeted treatment" [9] . Glynn and Greenland found only one such: Muller et al. developed a model that included clinical history variables and lung function measures to estimate 2-year probability of lung cancer, providing significant increased discriminatory power over and above a prevailing screening algorithm [10] .
Given that UK Biobank is in an early phase with a relatively short duration of follow-up, despite a large sample size, should we be concerned or even surprised regarding the paucity of novel findings with potentially direct clinical applicability? While continuous evaluation is essential, concern may be premature. For one, publication metrics are not the only measure of impact. High impact papers provide one metric, but UK Biobank data have catalyzed hundreds of publications in preprint servers like BioRxiv (https ://www. biorx iv.org/) and MedRxiv (https ://www.medrx iv.org/) that may precede and spawn follow-up research prior to actual publication in peer-reviewed journals. Further, given the unprecedented broad access to research using UK Biobank data, and the absence of a requirement for publication, access has been provided to largescale datasets of genomic summary results from phenome-wide GWAS that are publicly available via easily accessible browsers (for example, see http://www.neale lab.is/uk-bioba nk and http://phewe b.sph.umich .edu) that may be used for downstream basic and translational research in both academic and private sector prior to publication or validation in the peer-reviewed literature.
Review of funded research activities may provide another metric for evidence of translation of biobank research into precision medicine. While it may be premature to comprehensively evaluate translational research funding in recent biobanks like UK Biobank, recent evaluations of translational research funding during the current era of genomics/ GWAS suggest that most government research funding continues to focus heavily on discovery rather than translation. Recent studies of the United States National Institutes of Health grant funding portfolios that include GWAS show a large gap between the proportion of funded research grants focused on discovery compared with the limited proportion of funded research grants focused on clinical or population translational or implementation for heart, lung, and blood [11] or medical genomic research, largely focused on oncology [12] . Similar large gaps in "knowledge translation" are seen in examinations of international research funding [13] . While basic discovery science should remain a central priority of government research, these findings suggest that targeted funding may be essential to prioritize and catalyze translational research and to decrease the time from discovery to implementation.
Like the early prospective cohort studies such as the Framingham Heart Study, UK Biobank provides a powerful prospective biobank cohort example in the current Precision Medicine era for recently formed large international biobanks, such as the China Kadoorie Biobank [14] , the All of Us Research Program [15] , and the Veterans Administration Million Veteran Program [16] . The deep genomic, imaging, digital health technology, and multi-omic Rare, limited to inter-cohort Global, multi-ethnic cohorts Global, multi-biobank cohorts biomarker data collected in UK Biobank and other such biobanks may provide substantial opportunities to catalyze genomic medicine discoveries and to probe for refinement of genomic screening, incremental prediction, or treatment stratification. As one example, whole exome sequencing and whole genome sequencing in UK Biobank are providing among the largest single well-phenotyped cohorts to date with deep genome sequencing, allowing characterization of personal genomic profiles defined by the presence of rare, functional gene variants and the aggregation of common variants incorporated into polygenic risk scores. Such studies will refine our understanding of disease prevalence and/or evidence of drug responsiveness associated with "actionable" genomic findings [17] and pharmacogenomic variation. GWAS analysis for a wide range of clinical phenotypes in biobanks including UK Biobank are contributing to ever larger numbers of new genome wide significant loci, leading to a catalogue of potentially druggable gene targets [18] , and allowing for the updating and refinement of polygenic risk scores that are under intense scrutiny as potentially valid (pending further research) precision genomic instruments for prediction, screening or treatment. While Glynn and Greenland note the limited evidence of incremental predictive value in an initial cross-sectional study of polygenic risk scores that incorporates large numbers of SNPs [19] , these initial studies of polygenic risk scores in UK Biobank have opened the door for further comprehensive prospective genomic studies. Indeed, recent prospective genomic studies in UK Biobank suggests that cardiovascular disease risk prediction may be afforded by measuring both rare genetic variation and polygenic risk scores in UK Biobank [20] , though the incremental prediction is modest by polygenic risk scores alone [21] . Longer term studies with greater numbers of disease outcomes will certainly be required to validate and refine these estimates, and similar studies in non-European participants of other biobanks will be required to define generalizability to diverse populations. The ascendance of multiple large prospective biobank cohorts provides an unparalleled opportunity to conduct medical genomic and population science research at scales not previously imagined. The creation of a biobank nested within a nationwide health system or a regional medical center establishes a potential translational research platform for precision medicine in patients and populations. The UK Biobank provides a shining example of biobank data sharing that is acutely driving discovery research for which the promise and expectation of a new world of precision medicine remains to be fulfilled. High impact publications are but one metric and given an abundance of new genomic, other 'Omic and phenomic data being generated in UK Biobank and other biobanks, the next decade should provide a much clearer window into the pace, scale and breadth of translational findings from biobank research.
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